5-HT2B antagonists
AssigneeNational Institute of Biological Sciences, Beijing
InventorsNiu Huang, Yu Zhou, Xingyu Lin
Life of this patent
Estimating the term…
Abstract
The invention provides novel compounds and compositions comprising a 5-HT2B antagonist of formula I: and related methods for treating a person having a disorder characterized by undesirable 5-HT2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.
Claims20
A method for treating a person in need thereof having a disorder characterized by undesirable 5-HT2B receptor signaling, comprising administering to the person a 5-HT2B antagonist of formula I:
- wherein:
- R1 and R2 are independently H or methyl;
- R3 and R4 are independently a C1-C4 alkyl, or R3 and R4 are joined to form a C3-C8 cycloalkyl;
- and
- R5-R9 are independently H, halogen, hydroxyl, or an optionally substituted C1-C4 alkyl, C1-C4 alkyoxy, carbonyl, carboxyl, or amine;
- or salt thereof,
- wherein the disorder is migraine, pulmonary arterial hypertension (PAH), fibrosis, or a gastrointestinal (GI) tract disorder selected from the group consisting of hypertonic lower esophageal sphinter, irritable bowel syndrome (IBS), gastric motility disorder, dyspepsia, gastroesophageal reflux disease (GERD), and tachygastria.
Dependencies are inferred from the claim text.